Specialty Pharmacy

Research highlights the importance of reaching non-white and younger populations with skin cancer prevention messages.

Data from the BEACON CRC trial show encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer.

Pre-symptomatic infants with spinal muscular atrophy treated with nusinersen showed continuous improvement in achieving motor milestones.

Top news of the day from across the health care landscape.

Puma Biotechnology submitted a supplemental New Drug Application to the FDA for neratinib (Nerylnx) in combination with capecitabine for the treatment of patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Study finds elevated risk factors for cardiovascular disease in postmenopausal women with a history of breast cancer.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

New study demonstrates a novel approach of linking HER2-targeting antibodies with chemotherapy drugs for patients with breast cancer.

Top news of the day from across the health care landscape.

In an interview with Specialty Pharmacy Times, former NFL placekicker, Rolf Benirschke, CEO of Legacy Health Strategies, discusses how specialty pharmacists can best support patients who are undergoing treatment for IBD or Crohn Disease.

In an interview with Specialty Pharmacy Times, former NFL placekicker, Rolf Benirschke, CEO of Legacy Health Strategies, discusses how treatment for IBD and Crohn Disease has evolved for patients since his diagnosis in the late 1970s.

In an interview with Specialty Pharmacy Times, former NFL placekicker, Rolf Benirschke, CEO of Legacy Health Strategies, discusses why an effective communication channel is critical to achieving optimal outcomes for patients with IBD.

In an interview with Specialty Pharmacy Times, former NFL placekicker, Rolf Benirschke, CEO of Legacy Health Strategies, discusses how pharmacists can be there when counseling a patient who may have IBD or Crohen disease.

Research adds to a previously found correlation between yogurt consumption and a lowered risk of bowel cancer.

Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.

American Society of Health-System Pharmacists summer meeting included topics tied to the overarching themes of health system specialty pharmacy operations, clinical outcomes, and business development

Top news of the day from across the health care landscape.

Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate.

There are currently an estimated 8.1 million males and 8.8 million females in the United States with a history of cancer.

A protein called DDX3X has been found to regulate a melanoma-specific oncogene called MITF that is central to the development of the pigment cells in the skin.

Top news of the day from across the health care landscape.

A recent study analyzed the 10-year absolute risks of thromboembolism and bleeding in patients with a history of hematologic cancer.

Top news of the day from across the health care landscape.

A new study of patients treated with ophthalmology medications indicates that electronic health records may not contain accurate, up-to-date information.

CDc11+ dendritic cells are the first to interact with HIV and transmit the virus to other cells in the body.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Patients with psoriasis reported frequent use of complementary or alternative medicine, but less than half said they would recommend these therapies to others.

As young patients with bone cancer are often treated with high doses of chemotherapy before and after surgery, researchers wanted to develop gentler treatment options.

Selinexor (Xpovio, Karyopharm) received approval in combination with dexamethasone for heavily-pretreated patients with relapsed or refractory multiple myeloma.